SNDX

Syndax Pharmaceuticals, Inc. (SNDX) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Capital Allocation

Management maintains a very strong liquidity position with a current ratio of 6.77 and cash ratio of 3.38, giving it flexibility despite ongoing losses.

Capital structure remains highly leveraged on a book basis, with debt-to-equity at 39.03 and financial leverage at 46.60, which limits balance-sheet quality.

The company is still burning cash at the operating level, with operating cash flow TTM of -$135.4M and free cash flow TTM of -$135.4M, so capital allocation remains constrained by funding needs.

Execution

Execution remains mixed: gross margin is extremely high at 97.47%, but operating margin is still deeply negative at -77.05%, indicating strong product economics but weak operating discipline.

Working-capital efficiency remains poor, with a cash conversion cycle of 1,722.9 days and inventory turnover of just 0.19x, suggesting execution challenges in converting revenue into cash.

Revenue generation is still modest relative to the cost base, with revenue per share of 2.83 versus net income per share of -2.48, reinforcing that profitability has not yet scaled.

Incentives Alignment

No fresh news or compensation disclosures were provided this month, so there is no new evidence of a change in management incentives or alignment.

Given the continued losses and cash burn, alignment remains best judged by whether management can preserve liquidity while improving operating efficiency.

Track Record

No new news items were provided, so there is no fresh evidence to update management's recent track record.

The latest metrics still show a company that has not yet translated strong gross margins into durable profitability or positive free cash flow.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Syndax Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →